期刊文献+

近年结肠癌NCCN指南变化初探 被引量:3

Analyze Change of NCCN Clinical Practice Guidelines in Oncology
暂未订购
导出
摘要 NCCN结肠癌临床实践指南是基于丰富循证医学证据建立的高水平、规范化治疗指南。近年来,随着临床证据的不断丰富和积累,指南对一些临床问题的处理进行了调整,有的原则发生了变化。本文通过对历年不同版本指南的比较,对手术方式及病理评估、术后辅助化疗、晚期治疗方案和分子靶向治疗等几方面指导意见的变化进行了初步探讨分析。 NCCN Clinical Practice Guidelines in Oncology, which based on abundant evidence of EBM, provide a concise script to help us understand colon cancer. With the clinical evidence accumulated, management of some problem has been adjusted and some principles have been changed. Through comparing of the guidelines in different version, we analyze the change on principle of surgery and pathologic evaluation, adjuvant chemotherapy, management of disseminated metastatic colon cancer and molecular targeted therapy to direct our clinical work.
作者 刘慧龙
出处 《医学与哲学(B)》 2010年第3期11-13,47,共4页 Medicine & Philosophy(B)
关键词 结肠癌NCCN临床实践指南 变化 探讨 NCCN Clinical Practice Guidelines in Oncology, change, analysis
  • 相关文献

参考文献18

  • 1NCCN.NCCN结肠癌临床实践指南[EB/OL].(2005-02-05)[2010-02-25].http://www.nccn.org/professionals/physician_gls/PDF/colon.pal.
  • 2Jayne D G, Guillou, Thorpe H, et al. Randomized trial of laparoscopic--assisted resection of colorectal carcinoma: 3--year results of the UK MRC CLASICC trial group[J]. J Clin Oncol,2007,25: 3061-3068.
  • 3Kuhry E, Bonjer H J, Haglind E, et al. Impact of hospital case volume on short--term outcome after laparoscopic operation for colonic cancer[J]. Surg Endosc, 2005,19:687--692.
  • 4Johnson P M, Porter G A, Ricciardi R , et al. Increasing negative lymph node count is independently associated with improved long term survival in stage IIIB and IIIC colon cancer[J]. J Clin Oncol, 2006,24:3570--3575.
  • 5Berger A C, Sigurdson E R, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes[J]. J Clin Oncol,2005,23:8706--8712.
  • 6Yasuda K, Adachi Y, Shiraishi N, et al. Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer [J]. Ann Surg Oncol, 2001,8:300--304.
  • 7Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20 898 patients on 18 randomized trials[J]. J Clin Oncol, 2009,27 : 872- 877.
  • 8Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study[J]. Lancet, 2007,370 : 2020-- 2029.
  • 9Andre T, Boni C, Navarro M,et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial[J]. J Clin Oncol, 2009,27(19):3109-3116.
  • 10Sargent D, Marsoni S, Thibodeau S, et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5 -- FU based chemotherapy in stage II and III colon cancer (CC) : A pooled molecular reanalysis of randomized chemotherapy trials[J].J Clin Oncol, 2008,26 : a4008.

二级参考文献11

  • 1徐建明.大肠癌内科治疗现状的认识和评价[J].中华肿瘤杂志,2005,27(12):705-707. 被引量:13
  • 2Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med, 2000, 343:905-914.
  • 3Cadini LE, Meropol NJ, Bever J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabineJirinotecan. Clin Cancer Res, 2005, 11:1226-1236.
  • 4Saeki M, Saito Y, Jinno H, et al. Haplotype structures of the UGT1A gene complex in a Japanese population. Pharmacogenomics J, 2006, 6:63-75.
  • 5Gagne JF, Montminy V, Belanger P, et al. Common human UGT1 A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin ( SN-38 ). Mol Pharmacol, 2002,62:608-617.
  • 6Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin udp-glucuronosyltransferase 1 in gilbert's syndrome. N Engl J Med, 1995, 333:1171-1175.
  • 7Yamanaka H, Nakajima M, Katoh M, et al. A novel polymorphism in the promoter region of human UGT1A9 gene ( UGT1A9 &*22) and its effects on the transcriptional activity. Pharmacogenetics, 2004, 14:329-332.
  • 8Marcuello E, Mtes A, Menoyo A, et al. UGT1 A1 gene variations and irinotecan treatment in patients with metastatic colon cancer. Br J Cancer, 2004, 91:678-682.
  • 9Han JY, Lira HS, Shin ES, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol, 2006, 24:2237-2244.
  • 10Ando Y, Saka H, Ando M, et al. Polymorphisms of UDPglucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res, 2000, 60:6921-6926.

共引文献42

同被引文献23

引证文献3

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部